Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics


Dr. Reddy's Laboratories Ltd (RDY)

Today's Latest Price: $53.61 USD

0.60 (1.13%)

Updated Jul 15 12:40pm

Add RDY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RDY Stock Summary

  • Price to trailing twelve month operating cash flow for RDY is currently 0.23, higher than just 2.63% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of -41.16%, Dr Reddys Laboratories Ltd's debt growth rate surpasses just 6.64% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for RDY comes in at 275.79% -- higher than that of 98.28% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Dr Reddys Laboratories Ltd, a group of peers worth examining would be AGCO, OPK, XYL, VAR, and HAS.
  • RDY's SEC filings can be seen here. And to visit Dr Reddys Laboratories Ltd's official web site, go to www.drreddys.com.
RDY Daily Price Range
RDY 52-Week Price Range

RDY Stock Price Chart Technical Analysis Charts


RDY Price/Volume Stats

Current price $53.61 52-week high $55.19
Prev. close $53.01 52-week low $33.33
Day low $53.51 Volume 42,985
Day high $53.97 Avg. volume 216,758
50-day MA $52.14 Dividend yield 0.51%
200-day MA $44.38 Market Cap 8.88B

Dr. Reddy's Laboratories Ltd (RDY) Company Bio


Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.

RDY Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$53.61$2493.664752%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Dr Reddys Laboratories Ltd. To summarize, we found that Dr Reddys Laboratories Ltd ranked in the 95th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 4776.17%. As for the metrics that stood out in our discounted cash flow analysis of Dr Reddys Laboratories Ltd, consider:

  • The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately only 10.74% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • RDY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 50.45% of tickers in our DCF set.
  • As a business, Dr Reddys Laboratories Ltd experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than just 0% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%4657%
1%4705%
2%4752%
3%4800%
4%4848%
5%4895%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as RDY, try THC, VASO, DVCR, CORT, and FVE.


RDY Latest News Stream


Event/TimeNews Detail
Loading, please wait...

RDY Latest Social Stream


Loading social stream, please wait...

View Full RDY Social Stream

Latest RDY News From Around the Web

Below are the latest news stories about Dr Reddys Laboratories Ltd that investors may wish to consider to help them evaluate RDY as an investment opportunity.

Dr. Reddy's launches generic nicorette lozenges in U.S.

Dr. Reddy’s Laboratories (RDY) announces the launch of Over-the-Counter ((OTC)) Nicotine Polacrilex Lozenges, 2 mg and 4 mg in the U.S., the store brand version of GlaxoSmithKline's Nicorette Lozenges. The Nicotine Lozenges brands and store brand markets had total U.S. retail sales of ~$200M for the year ended May 17, according...

Seeking Alpha | July 14, 2020

Dr. Reddy's Laboratories announces the launch of Over-The-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. Market

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Over-the-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette® Lozenges in the U.S. market.

Yahoo | July 14, 2020

Dr. Reddy's goes ex-dividend tomorrow

Dr. Reddy's (RDY) declares INR 25.00/share annual dividend.For shareholders of record July 13; ex-div July 10.See RDY Dividend Scorecard, Yield Chart, & Dividend Growth....

Seeking Alpha | July 9, 2020

India's Cipla set to undercut rivals with generic remdesivir -sources

Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally. Cipla had earlier said pricing would not exceed 5,000 rupees. On Tuesday, Sovereign Pharma, which is manufacturing and packaging the drug for Cipla, said it had dispatched the first batch.

Yahoo | July 8, 2020

Overall performance may be quite volatile in FY21 due to coronavirus: Dr Reddy’s

Dr Reddy's Laboratories expects its overall performance to be "quite volatile" in the current fiscal with uncertainties related to COVID-19 set to increase during the period, the company said in its Annual Report for 2019-20.

The Financial Express | July 6, 2020

Read More 'RDY' Stories Here

RDY Price Returns

1-mo 0.08%
3-mo 6.20%
6-mo 26.96%
1-year 40.17%
3-year 30.68%
5-year -10.25%
YTD 32.81%
2019 8.38%
2018 1.18%
2017 -16.47%
2016 -1.67%
2015 -7.76%

RDY Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full RDY Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9191 seconds.